Delve into the increasingly dynamic landscape of ALS treatment development with thirteen companies advancing candidates in 2025.

As the year unfolds the biotech industry will look closely at these ten first-in-class drugs on track to reach FDA approval ...

The month of December 2024 saw a variety of biotech deals take place to advance therapies across different stages in ...

Explore advances in von Willebrand disease treatment, including Star Therapeutics' VGA039, and other key players in the space ...

Last year, we took a look at the biotech trends that we thought would shape 2024. Now, as we enter the new year, the biotech industry is continuing to evolve at a rapid pace, and 2025 is shaping up to ...

A blockbuster drug is a therapy that generates at least $1 billion in sales. Clarivate’s Drugs to Watch 2025 report includes treatments that were approved last year or expected to debut this year and ...

Various PD-1 and PD-L1 checkpoint inhibitors have been approved by U.S. regulators including blockbuster drugs Keytruda, Imfinzi, and Opdivo to treat different types of cancer. But that hasn’t stopped ...

CRISPR-Cas9 is one of the biggest discoveries of the 21st century. Since it was developed in 2012, this gene-editing tool has revolutionized biology research, making it easier to study disease and ...

In the last year or so, there have been a number of indications that Saudi Arabia is setting itself up to become a global biotech hub. Over the next decade, it is expected to become a world leader in ...